<DOC>
	<DOCNO>NCT01337609</DOCNO>
	<brief_summary>The purpose study determine safety effectiveness nutritional supplement , probiotic bacteria GanedenBC30 . Probiotics live microorganism take large enough amount suppose provide health benefit . The investigator would like see whether supplement use treatment Irritable Bowel Syndrome ( IBS ) Major Depressive Disorder ( MDD ) . Participants study IBS MDD . In order find GanedenBC30 effective treat IBS MDD , investigator compare placebo . About 32 people take part research study . About half 32 people take part Charles River Medical Associates half take part Burlington Medical Associates . Participants recruit among patient already see Charles River Medical Associates Burlington Medical Associates primary care . The study last two month , time participant make eight study visit take either Ganeden BC30 placebo . The investigator hypothesize subject treat probiotic significantly well outcomes regard depression IBS symptom compare receive placebo .</brief_summary>
	<brief_title>Study Probiotic GanedenBC30 Irritable Bowel Syndrome Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>Able give Informed Consent Meet criterion Irritable Bowel Syndrome Meet criterion Major Depressive Disorder Men woman age 18 65 Women childbearing potential must use adequate method contraception Can antidepressant medication , must medication least 8 week stable dose 4 week Can medications IBS , must medications least 8 week stable dose 4 week Patients fail one trial probiotic IBS Patients report inadequate response less two four adequate trail antidepressant treatment current depressive episode therapeutic dose adequate duration Women pregnant breastfeeding Patients `` alarm sign '' `` red flag '' define American Gastroenterological Association ( AGA ) exclude [ 6 ] , unless fully evaluate rule significant disease . Patients know diagnosis digestive organic disease , celiac disease lactose intolerance prior screen . Patients report inadequate response ( le 50 % decrease depressive symptom severity ) less two four prior adequate trial antidepressant treatment current depressive episode ( include monotherapy treatment distinct combination regimen ) therapeutic dose ( defined MGHATRQ ) adequate duration ( minimum six week monotherapy ) . Patients report treatment adjunctive medication antidepressant minimum four week current depressive episode . Patients current need involuntary commitment hospitalize within four week Screening Visit current major depressive episode . Patients receive ECT current episode . Patients current Axis I diagnosis : Delirium , dementia , amnestic , cognitive disorder ; Schizophrenia psychotic disorder , base PDSQ ; Bipolar I II disorder , base PDSQ ; Patients clinically significant Axis II ( DSMIVTR ) diagnosis borderline , antisocial , paranoid , schizoid , schizotypal histrionic personality disorder . Patients experience hallucination , delusion , psychotic symptomatology current depressive episode . Patients meet DSMIVTR criterion significant substance use disorder within past six month , base PDSQ . Patients receive new onset depressionfocused psychotherapy within 6 week screen , time participation trial . Patients previously randomize probiotic clinical trial ( lifetime ) . Patients participate clinical trial investigational drug device within past month . Patients , opinion investigator , actively suicidal homicidal significant risk suicide homicide .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Depression</keyword>
	<keyword>Irritable Bowel Syndrome</keyword>
	<keyword>Probiotic</keyword>
	<keyword>Bacillus Coagulans</keyword>
</DOC>